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Long-term oral antibiotic treatment:
why, what, when and to whom?
Eva Van Braeckel1 and Menno M. van der Eerden2
Antibiotics are typically prescribed as short courses for acute infections, in order to reduce
bacterial load, shift the balance in favour of host defences and thus help to overcome
infection. Over the past decade, however, interest in the long-term anti-inflammatory and
immunomodulatory effects of selected antibiotics has been on the increase. Since the clinical
effectiveness of erythromycin was reported in diffuse panbronchiolitis in the 1980s, the use
of macrolides has been adopted into many other chronic inflammatory airway diseases
characterised by frequent exacerbations, including cystic fibrosis (CF), non-CF
bronchiectasis, COPD, severe noneosinophilic asthma, bronchiolitis obliterans after lung
transplantation and organising pneumonia. In this chapter, we discuss the indications and
limitations of long-term macrolide treatment in these chronic respiratory conditions.
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Antibiotics are typically prescribed as short courses for acute infections, in order toreduce bacterial load, shift the balance in favour of host defences and thus help to
overcome infection. Over the past decade, however, interest in the long-term
anti-inflammatory and immunomodulatory effects of selected antibiotics has been on the
increase. Here, we discuss the indications and limitations of long-term macrolide treatment
in these chronic respiratory conditions.
Long-term oral antibiotic treatment: why?
Airway disorders such as COPD, cystic fibrosis (CF) and bronchiectasis, in which chronic
airway inflammation and (infectious) exacerbations occur, typically result in progressive
lung function decline, decreased health-related quality of life and increased risk of mortality
[1–5]. The pathophysiological processes typical of these chronic inflammatory lung diseases
are characterised by a vicious circle hypothesis, in which exacerbations result in increased
airway inflammation, more damage to airways and therefore a higher risk for new
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exacerbations, which will finally result in progression of disease (figure 1) [4, 6, 7]. To
inhibit further disease progression, interventions have to be performed directed at one of
these steps of the vicious circle. Among these interventions is the implementation of
long-term oral antibiotic treatment. The most widely studied class of antibiotics used for
oral maintenance therapy is the macrolide group.
Long-term oral antibiotic treatment: what?
Choice of agent
Although other antibiotics, such as the tetracycline doxycycline and the fluoroquinolone
moxifloxacin, have also been assigned immunomodulatory properties [8, 9], only the use of
macrolides has been well documented in RCTs. Their effects in chronic inflammatory lung
diseases were first studied in patients with diffuse panbronchiolitis in the 1980s [10].
Since then macrolides have been studied extensively in CF [11–14], non-CF bronchiectasis
[15–17], and recently also in patients with COPD [18–20] and severe asthma [21, 22].
Structure and mechanisms of actions of macrolides
The family of macrolide antibiotics is structurally characterised by a lactone ring containing
at least 12 members, with erythromycin, clarithromycin and roxithromycin containing a
14-membered lactone ring, and azithromycin (also called an azalide) containing a
15-membered lactone ring with a tertiary amino group [23, 24]. The neomacrolides
azithromycin, clarithromycin and roxithromycin have excellent bioavailability with superior
oral absorption and better tissue penetration than erythromycin, accumulating preferentially in
(alveolar) macrophages, with azithromycin having the longest serum half-life, making it
suitable for once-daily or even intermittent dosing [25–27]. Due to toxicity concerns and
scarceness of data on immunomodulatory effects, the ketolide telithromycin is less convenient
for long-term use and will therefore not be discussed further in this chapter [28–30].
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Figure 1. Vicious circle hypothesis of chronic inflammatory pulmonary disorders [6].
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Figure 2. The antimicrobial and immunomodulatory effects of macrolides. a) Antimicrobial effects. Macrolides can directly affect bacteria by inhibiting bacterial protein
synthesis, and reducing their adherence and toxin production. In addition, they are able to disrupt biofilm formation through suppression of quorum sensing proteins,
in particular in the case of Pseudomonas aeruginosa infections. Macrolides stimulate phagocytosis of pathogenic bacteria by alveolar macrophages. In bronchial
epithelial cells, they tend to induce antiviral host responses, thereby indirectly hampering viral replication. b) Immunomodulatory effects. Macrolides enhance
mucociliary clearance by reducing airway secretions through inhibition of neutrophil elastase and modulation of mucin gene expression, and reduce chronic
inflammation by stimulating phagocytosis of apoptotic cells and impairing the production of pro-inflammatory mediators such as IL-8 in airway epithelial cells and
alveolar macrophages [53].
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Antimicrobial effects of macrolides
The direct antibiotic effect of macrolides is exerted through binding to the bacterial 50S
ribosomal subunit, thereby interfering with its assembly and ultimately inhibiting bacterial
protein synthesis, leading to a bacteriostatic effect [25, 31, 32]. Their antibacterial spectrum
primarily includes the atypical bacteria Chlamydophila pneumoniae, Mycoplasma
pneumoniae and Legionella pneumophila, and, although resistance is on the increase,
Gram-positives such as Streptococcus pneumoniae, while the neomacrolides also have a
better Gram-negative coverage, including susceptible strains of Haemophilus influenzae and
Moraxella catarrhalis [25, 33, 34]. The neomacrolides clarithromycin and azithromycin
have excellent tissue penetration, and hence form the backbone in first-line combination
treatment regimens for NTM such as MAC [35, 36]. Acquired resistance to macrolides
occurs through alterations in their binding site on the bacterial ribosomal RNA induced by
methylases encoded by erythromycin ribosome methylase (erm) genes or through
macrolide efflux (mef ) genes encoding for active efflux pumps reducing intrabacterial
macrolide concentrations [37, 38].
Indirect antimicrobial effects are established by stimulation of phagocytosis of bacteria by
alveolar macrophages [39, 40], and via inhibition of quorum sensing and biofilm
formation, mechanisms which have been proven particularly useful in reducing the
virulence of Pseudomonas aeruginosa and facilitating the effects of antipseudomonal
antibiotics [41–43]. At subinhibitory concentrations, azithromycin interferes with cell–cell
communication through inhibition of the guanosine diphosphomannose dehydrogenase
enzyme in the alginate biosynthetic pathway of mucoid P. aeruginosa strains, thereby
mitigating biofilm production [44]. Interestingly, an increase in the expression level of type
III secretion system genes, encoding for virulence factors in P. aeruginosa, has also been
observed in vitro, but up to now without any clinical correlate [44, 45].
Supported by the observation that erythromycin significantly reduced the number of common
colds in COPD patients [46], potential antiviral properties of macrolides have also been
unravelled more recently [47–49]. In vitro, azithromycin decreases viral load in bronchial
epithelial cells infected with rhinovirus [49]. Its antiviral effects are possibly mediated by
induction of pattern recognition receptors, IFNs and IFN-stimulated genes, leading to a global
amplification of the host antiviral response to human rhinoviruses [47, 48]. The antimicrobial
effects of macrolides are summarised in figure 2a.
Immunomodulatory effects of macrolides
Long-term treatment courses with 14- and 15-membered-ring macrolides are known to
influence chronic airway diseases mediated by neutrophilic inflammation [50–53]. In
contrast to other antibiotics that have been attributed immunomodulatory effects,
macrolides are known to alter a plenitude of cells within the airway, including neutrophils,
alveolar macrophages, lymphocytes and epithelial cells [54, 55]. The pronounced
intracellular accumulation and retention of macrolides, and in particular of azithromycin,
allows prolongation of their effects within host cells [56, 57]. After an initial stimulation of
neutrophil degranulation and phagocytosis-associated oxidative burst enhancing their
antibacterial activity, late effects of macrolides include increased neutrophil apoptosis and
attenuation of oxidative burst responses [55, 56]. Neutrophilic inflammation is further
hampered by macrolide antibiotics through decreased production of chemoattractants and
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decreased expression of adhesion molecules, resulting in attenuation of chemotaxis [58, 59].
Azithromycin may also promote differentiation of monocytoid cell lines into macrophages
and alter the macrophage phenotype, leading to reduced secretion of pro-inflammatory
cytokines and increased production of anti-inflammatory mediators [60–62]. In addition,
macrolides stimulate phagocytosis of apoptotic cells by alveolar macrophages [39, 40],
attenuate type 1 T-helper cell (Th1) responses following lipopolysaccharide (LPS)- or
IFN-γ-induced stimulation of macrophages, and (although conflicting observations have
been reported) seem to affect the balance between Th1 and Th2 responses [63–65].
Additional modulation of host defence occurs through interaction with structural cells,
such as bronchial epithelial cells, with beneficial effects on the stability of the epithelial
barrier and ciliary function [54, 55]. Macrolide-induced inhibition of neutrophilic elastase
and matrix metalloproteinases [66–68], and of respiratory epithelium cytokine production
[56, 68, 69], is well established. Most of these effects are probably caused by modulation of
mitogen-activated protein kinase and NF-κB signalling pathways [54]. In human airways,
epithelial goblet cells and mucous cells synthesise gel-forming mucins such as MUC5AC
and MUC5B [54]. Erythromycin and clarithromycin have been shown to inhibit this
TNF-α-induced mucus secretion, resulting in improved mucociliary clearance and hence
beneficial effects in various clinical conditions characterised by excessive sputum
production [51, 70, 71]. The immunomodulatory effects of macrolides are summarised in
figure 2b.
Dosing of macrolides
The long half-life and interesting safety profile makes azithromycin the agent of choice for
long-term use. When used for its immunomodulatory purposes, azithromycin is typically
dosed as 500 mg three times weekly on Monday, Wednesday and Friday (MWF), or
alternatively by a daily 250 mg dose, although the AZISAST (Azithromycin in severe asthma)
study has shown efficacy in noneosinophilic asthma at lower doses of 250 mg three times
weekly [21]. In case of intolerance of the usual dosage, lower doses of 250 mg MWF are
worth considering as, although not widely studied, they might have the advantage of
inducing less adverse events without losing efficacy. In case of obstinate gastrointestinal
intolerance of azithromycin, roxithromycin can be used as an alternative, at a daily dose of
150 mg [72]. As for clarithromycin, most clinical trials have been performed with doses of
500 mg twice daily, although doses as low as 200 mg daily have also proven effective [68, 73].
Other antibiotics
In addition to macrolides, other antibiotics have been investigated, although less intensively,
for maintenance treatment in chronic inflammatory airway diseases. Doxycycline and other
tetracyclines have been shown to regulate the host immune response, e.g. by targeting
matrix metalloproteinases released from neutrophils and attenuating LPS-induced
inflammation [8, 74, 75]. Immunomodulatory effects have also been attributed to
fluoroquinolones, with moxifloxacin selectively inhibiting secretion of cytokines such as
IL-8 and IL-6, and NF-κB activation in CF epithelial cell lines, and ciprofloxacin providing
anti-inflammatory properties in the setting of LPS-induced lung injury in animal models
[76, 77]. In Stenotrophomonas maltophilia infection, trimethoprim–sulfamethoxazole
(cotrimoxazole) has been shown to suppress TNF-α production by human peripheral blood
mononuclear cells [78]. Accumulating in vitro evidence suggests that cotrimoxazole is able
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to enhance neutrophil chemotaxis, phagocytosis and intracellular killing by macrophages,
to reduce lymphocytic proliferation [79]. As mentioned earlier, this chapter will elaborate
mainly on the clinical applications of macrolides as only scarce data on the long-term use
of other oral antibiotic treatment classes are available.
Long-term oral antibiotic treatment: when and to whom?
Diffuse panbronchiolitis
Diffuse panbronchiolitis is an idiopathic inflammatory disease of the respiratory
bronchioles, almost exclusively occurring in Japan and other East Asian countries [80, 81].
This progressive disease is characterised by neutrophilic airway inflammation with elevated
pro-inflammatory cytokines such as IL-8 and IL-1β, and often complicated by
H. influenzae and/or P. aeruginosa infection [82, 83]. The prognosis of this possibly fatal
disease was significantly improved by the introduction of erythromycin, leading to the
suspicion of beneficial effects of erythromycin other than its antibacterial activity [10, 84].
Treatment with macrolides has been shown to decrease BAL fluid levels of neutrophils,
IL-8 and pro-inflammatory β-defensins [83, 85, 86]. Nevertheless, most evidence came
from retrospective or prospective open trials, suggesting not only efficacy of erythromycin
[10, 84, 87, 88], but also of clarithromycin, azithromycin and roxithromycin [73, 89–91].
Only one small RCT was reported examining serial CT scans [92]. As the overt clinical
success of macrolide treatment precludes placebo-controlled trials in diffuse
panbronchiolitis, the authors of a systematic review instead recommended setting up
comparative RCTs between different kinds or doses of macrolides in the future [93].
Cystic fibrosis
CF is a multisystem, autosomal recessive genetic disease, caused by a defect in the CF
transmembrane conductance regulator (CFTR) gene. Its pulmonary manifestations are
characterised by recurrent airway infections, chronic inflammation and progressive lung
function decline, resulting in limited life expectancy [94, 95]. However, the prognosis is
gradually improving due to the introduction of medication directly targeted to the genetic
cause of the disease, as well as treatments directed towards infection and inflammation [96,
97]. Frequent pulmonary exacerbations are known to be associated with increased
mortality. Macrolides, which in CF will mainly have anti-inflammatory and antibacterial
working mechanisms by inhibiting biofilm formation (figure 2), have been investigated for
their potential to improve lung function in CF in five large RCTs (table 1) [11–14, 98].
Forced expiratory volume in 1 s (FEV1) improved in two studies and azithromycin reduced
FEV1 decline in one study. Although two other trials did not show an effect of macrolides
on FEV1, a reduction in the number of exacerbations was established. The 2012 Cochrane
review on macrolide maintenance therapy in CF stated that 6-month azithromycin
treatment courses can result in improved FEV1 and reduced exacerbation rates, but that it
is not clear whether this effect will be sustained [99]. What is the effect of treatment with
macrolides longer than 12 months [100]? This important issue has recently been addressed
in a retrospective study showing that in the 2 years following the first year of azithromycin
treatment, the exacerbation rate increased again to levels similar to the period before
starting the macrolide [101].
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Table 1. Randomised double-blind placebo-controlled trials with long-term macrolides in cystic fibrosis (CF) and non-CF bronchiectasis
First author [ref.] Inclusion criteria Intervention Length of
treatment
Primary
outcome
Number of
exacerbations
CF
SAIMAN [12] Age ⩾6 years; weight ⩾25 kg;
chronic infection with Pseudomonas
aeruginosa
Azithromycin 250 or
500 mg (weight <40 or
⩾40 kg) three times
weekly
168 days Significantly
improved FEV1
Significantly reduced
(hazard ratio 0.65)
CLEMENT [11] Age 6–21 years Azithromycin 250 or
500 mg (weight <40 or
⩾40 kg) three times
weekly
12 months No significant
difference
in FEV1
Significantly reduced
(rate ratio 0.5)
EQUI [13] Age 8–18 years Azithromycin 250 or
500 mg (weight <40 or
⩾40 kg) once daily
6 months Significantly
improved FEV1
No significant
difference
WOLTER [14] Age ⩾18 years Azithromycin 250 mg
once daily
3 months Reduced rate of
FEV1 decline
No significant
difference
SAIMAN [98] Age 6–18 years; weight ⩾18 kg;
no Pseudomonas infection
Azithromycin 250 or
500 mg (weight <36 or
⩾36 kg) three times
weekly
168 days No significant
difference
in FEV1
50% reduction in
exacerbations
(hazard ratio 0.5)
Non-CF bronchiectasis
WONG [15] Age ⩾18 years; ⩾1 exacerbation
requiring antibiotic(s) in
preceding year
Azithromycin 500 mg
three times weekly
6 months Significantly reduced number of
exacerbations (rate ratio 0.38)
SERISIER [17] Age 20–85 years; ⩾2 exacerbations
requiring antibiotic(s) in
preceding year
Erythromycin 400 mg
twice daily
48 weeks Significantly reduced number of
exacerbations (rate ratio 0.57)
ALTENBURG [16] Age ⩾18 years; ⩾3 LRTIs requiring
antibiotic(s) in preceding year;
⩾1 sputum culture yielding
⩾1 bacterial pathogen in
preceding year
Azithromycin 250 mg
once daily
52 weeks Significantly reduced number of
exacerbations (rate ratio 0.41)
FEV1: forced expiratory volume in 1 s.
https://doi.org/10.1183/2312508X.10005416
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To whom?
As macrolides have a positive effect on lung function and exacerbation frequency, it can be
suggested to start this treatment in CF patients showing lung function decline or
experiencing frequent exacerbations.
Non-CF bronchiectasis
Bronchiectasis is defined as the presence of dilated thick-walled bronchi caused by chronic
bronchial inflammation and recurrent airway infections [4]. Many aetiologies have been
identified, with the most common causes described in the European Bronchiectasis Registry
(EMBARC) being idiopathic (39%) and post-infective (27%). Long-term oral antibiotics
were used in 19.4%, consisting mainly (in 74.2%) of azithromycin [102]. One RCT
evaluated amoxicillin 3 g twice daily for 32 weeks in bronchiectasis patients expectorating
daily purulent sputum, which resulted in a reduction in 24-h sputum volume and
purulence, and in symptom awareness [103]. Most recent trials have, however, been
examining macrolides mainly based on their anti-inflammatory properties and antibacterial
effects by inhibiting biofilm formation (figure 2). The three main randomised double-blind
placebo-controlled studies investigating the effect of azithromycin in non-CF bronchiectasis
have shown significant reductions in pulmonary exacerbations (table 1) [15–17]. In the trial
conducted by WONG et al. [15], the benefits of macrolide treatment persisted for 6 months
after completion of treatment. SERISIER et al. [17] showed that low-dose erythromycin also
decreased sputum production, with a beneficial effect on lung function, and increased
eradication of sputum pathogens.
To whom?
Based on the three trials [15–17], expert opinion supports macrolide maintenance
treatment in patients with frequent exacerbations (at least two exacerbations in the previous
year) provided their airway clearance techniques have been already optimised. Patients who
are stable with good self-reported quality of life and less pulmonary complaints should not
be treated with long-term azithromycin [104, 105].
COPD
COPD is defined by progressive airflow obstruction that is poorly reversible and
intercurrent acute exacerbations, which have an impact on disease course and mortality risk
[3, 106, 107]. Increasing evidence supports an important role for the lung microbiome in
the pathogenesis of COPD [108]. Exacerbations are often caused by infectious
microorganisms, accompanied by airway and systemic inflammation [109]. Prevention of
exacerbations is therefore essential to inhibit further disease progression. During
exacerbations, microbiome shifts have been observed, as well as differences related to the
exacerbation phenotypes described as bacterial or eosinophilic, with increases in
Proteobacteria (mainly Haemophilus and Moraxella spp.) or Firmicutes (mainly Streptococcus
spp.), respectively [108, 110]. A UK retrospective cohort study demonstrated that
maintenance antibiotic treatment (⩾6 months) had been prescribed only for a small
proportion of COPD patients (0.61%). The antibiotics most often used were oxytetracycline,
doxycycline and penicillin, with a rise in macrolide prescriptions from 2005 [111].
Many antibiotics have been assessed for long-term treatment in COPD. As early as 1956,
an observational study published in The Lancet showed overall improvement in 60% of
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patients with chronic bronchitis receiving tetracyclines during 6 months in winter. H.
influenzae was present in sputum cultures in almost all patients [112]. In contrast, a recent
RCT examining a 3-week course of doxycycline in stable COPD patients was not able to
show any anti-inflammatory effects [113]. Another observational study published in 1975
showed that an improvement in sputum production and dyspnoea was seen in 50% of
COPD patients with chronic sputum production receiving trimethoprim–sulfamethoxazole
960 mg twice daily during 3 months [114]. Recently, intermittent pulsed therapy with
moxifloxacin 400 mg once daily for 5 days, repeated each 8 weeks during 48 weeks, reduced
the exacerbation rate in COPD patients in an RCT [115].
In addition to their anti-inflammatory functions, macrolides can play a major role in
prevention of exacerbations due to their antibacterial and antiviral properties (figure 2).
Three major studies have investigated the role of macrolides in reducing exacerbations
(table 2). While UZUN et al. [18] included patients with frequent exacerbations, patients
with nonfrequent exacerbations were also allowed to be enrolled in the other two studies
[19, 20]. Macrolides reduced the number of exacerbations in all three trials [18–20]. The
beneficial effect of macrolides can be partially explained by the presence of bronchiectasis
in patients with COPD. MARTÍNEZ-GARCÍA et al. [116] showed that bronchiectasis was
present in almost 60% of the COPD patients. In the COLUMBUS (COPD: influence of
macrolides on exacerbation frequency in patients) trial, CT scans were performed to
exclude patients with bronchiectasis [18]. A multicentre RCT examining the effect of
short-term macrolide treatment in acute COPD exacerbations is currently ongoing [117].
To whom?
Criteria were proposed for selecting patients for long-term azithromycin treatment. In two
reviews, the authors recommend to prescribe macrolides in patients with frequent
exacerbations (at least two in the year before treatment) [17, 118]. The most pronounced
effect of azithromycin was seen in patients of older age, in those classified in lower Global
Initiative for Chronic Obstructive Lung Disease (GOLD) grade and in those not actively
smoking [119]. However, this analysis was performed on data which also involved patients
with nonfrequent exacerbations.
Severe noneosinophilic asthma
Severe asthma is a heterogeneous syndrome characterised by chronic airway inflammation,
either of eosinophilic nature or of noneosinophilic origin (neutrophilic or paucigranulocytic)
[120]. In parallel to the chronic neutrophilic airway diseases mentioned previously, the
effects of low-dose macrolides have also been examined in patients with severe
noneosinophilic asthma [53]. Initially, the observed beneficial effects of macrolides in asthma
were attributed to their antimicrobial properties directed towards intracellular pathogens,
such as Chlamydophila and M. pneumoniae [121, 122]. As with respiratory viral infections,
infection with and/or reactivation of these atypical bacteria has been associated with both
asthma exacerbations and chronic severe asthma [123–125]. Increased susceptibility to
infection in asthma probably leads to increased atypical bacterial infection (mainly with
C. pneumoniae), which itself then further increases neutrophilic airway inflammation by
eliciting acute antibody responses such as IgA, leading to aggravation of asthmatic symptoms
[124, 125]. Although a partial contribution of their bacteriostatic effects cannot be excluded,
it is widely assumed that the immunomodulatory properties of macrolides are the predominant
mechanism of action [126, 127]. Whereas shorter-term trials were only able to show some
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Table 2. Randomised double-blind placebo-controlled trials with long-term macrolides in COPD and severe asthma
First author [ref.] Inclusion criteria Intervention Length of
treatment
Primary outcome
COPD
UZUN [18] Age ⩾18 years; ⩾3 exacerbations
in the preceding year
Azithromycin 500 mg
three times weekly
12 months Significantly reduced number of
exacerbations (rate ratio 0.60)
ALBERT [19] Age ⩾40 years; FEV1 <80% predicted;
either use of continuous supplemental
oxygen or receipt of systemic
corticosteroids within the
previous year
Azithromycin 250 mg
once daily
12 months Significantly reduced number of
exacerbations (rate ratio 0.83)
SEEMUNGAL [20] FEV1 30–70% predicted; no
exacerbation required
Erythromycin 250 mg
twice daily
12 months Significantly reduced number of
exacerbations (rate ratio 0.65)
Severe asthma
BRUSSELLE [21] Age 18–75 years; persistent asthma (GINA
step 4 or 5); ⩾2 severe asthma
exacerbations requiring systemic
corticosteroids and/or LRTIs requiring
antibiotic(s) within previous year
Azithromycin 250 mg
three times weekly
6 months No difference in rate of severe
exacerbations and LRTIs requiring
antibiotic(s); significantly reduced number
of LRTIs and exacerbations in predefined
noneosinophilic severe asthma subgroup
(rate ratio 0.43)
HAHN [22] Age ⩾18 years; persistent asthma Azithromycin
600 mg weekly
12 weeks
(1 year
follow-up)
No difference in symptom control, except
for open-label group with more severe
asthma; not powered to detect differences
in exacerbation rate
FEV1: forced expiratory volume in 1 s; GINA: Global Initiative for Asthma.
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effect of macrolides on reduction of symptoms and improvement of lung function in severe
asthma, insufficient to recommend their routine use for asthma control [68, 128–132], the
AZISAST study was the first to examine the prevention of exacerbations as a primary
end-point in adults with exacerbation-prone severe asthma receiving long-term (6 months)
macrolide maintenance therapy (table 2) [21]. In contrast, clinical trials on short-term
macrolide treatment in acute asthma exacerbations yielded conflicting results [133–135].
To whom?
In the AZISAST randomised double-blind placebo-controlled trial, low-dose (250 mg three
times weekly) azithromycin treatment was only associated with a significant lower
exacerbation rate in the predefined subgroup of patients with noneosinophilic severe asthma
[21]. The need for a careful selection of patients can also be derived from the AZMATICS
(Azithromycin/asthma trial in community settings) trial, where a 12-week macrolide
treatment course only showed clinical improvement in an open-label study arm
encompassing individuals with severe treatment-resistant or refractory asthma [22]. However,
as a recent Cochrane review points out, there is still a need for additional high-quality studies
to confirm the possible benefit of macrolides in noneosinophilic severe asthma [136].
Other indications
Azithromycin has also proven useful in bronchiolitis obliterans syndrome (BOS) after lung
transplantation [137, 138]. This major complication of lung transplantation is a form of
chronic rejection associated with poor survival, defined as a delayed allograft dysfunction
with persistent decline in FEV1 without any other known and potentially reversible cause
[139, 140]. After encouraging data showing improvements in FEV1 in observational studies
[141, 142], CORRIS et al. [143] have recently shown efficacy of azithromycin treatment in
improving FEV1 in lung allograft BOS in an RCT. In lung transplant recipients, azithromycin
prophylaxis might even prevent the occurrence of BOS [144, 145]. These findings might also
be extrapolated to the similar condition of BOS complicating haematopoietic stem cell
transplantation; however, the scarce and rather small clinical trials available have not been
able to show a significant benefit of azithromycin in this population [146–148].
Organising pneumonia, either cryptogenic, or induced by infections, drug toxicity,
vasculitis or other conditions, is an inflammatory disorder characterised by buds of
granulation tissue in the peripheral airways and alveoli, preferably treated with systemic
corticosteroids [149]. On a case-by-case basis, chronic macrolide treatment may be
adjuvant to steroid therapy or act as a steroid-sparing strategy, probably through inhibition
of IL-8 release and neutrophil accumulation in the distal airways [150–154].
Long-term oral antibiotic treatment: is it safe?
Drug interactions
Drug interactions of macrolides are mainly mediated by inhibition of hepatic cytochrome
CYP (P450) 3A enzymes, but are least pronounced for azithromycin compared with
clarithromycin and erythromycin [155]. Through inhibition of CYP3A4, clarithromycin
and erythromycin have the propensity of inducing toxic concentrations of a long list of
substrates, including most statins, calcium channel blockers, amiodarone and colchicine. As
an inhibitor of glycoprotein P, however, azithromycin and the other neomacrolides are able
https://doi.org/10.1183/2312508X.10005416 195
LONG-TERM ORAL ANTIBIOTIC TREATMENT | E. VAN BRAECKEL AND M.M. VAN DER EERDEN
Purchased by ,  
From: European Respiratory Society Publications (reader.erspublications.com)
to increase plasma concentrations of various substrates such as digoxin, everolimus,
sirolimus, tacrolimus and posaconazole. All macrolides can cause altered warfarin levels to
various extent. Interactions with concomitant medication should therefore always be
checked before treatment initiation.
Adverse reactions
To date, no RCTs have thoroughly assessed the long-term safety of chronic macrolide
therapy. Typical side-effects include gastrointestinal discomfort such as nausea, diarrhoea
and abdominal pain, induced by dose-related effects on motilin receptors [156]. These
mild-to-moderate symptoms seldom lead to drug discontinuation (reviewed in [157]) and
are less frequently reported with the neomacrolides than with erythromycin [158, 159].
Within the neomacrolides, azithromycin and roxithromycin tend to induce fewer
gastrointestinal complaints than clarithromycin.
While severe hepatotoxicity is rare during azithromycin treatment, transient cholestasis or
other abnormal liver function tests have been described, although less frequently than with
erythromycin [158–160]. Its propensity to induce severe hepatotoxicity excludes
telithromycin from long-term treatment indications [28–30]. During long-term
azithromycin treatment, monitoring of serum liver enzymes is advisable and treatment
should be discontinued immediately if signs or symptoms of hepatitis occur.
The incidence of cardiac events has mainly been monitored in clinical trials on short-term
macrolide use [161, 162]. In particular, macrolide antibiotics are known to potentially
induce QT prolongation and torsades de pointes [161, 163]. Hence, azithromycin still
needs to be used with caution in patients with pre-existing cardiovascular disease and risk
factors [164, 165]. Before treatment initiation, measurement of the QT interval by
electrocardiography is recommended, in particular in the case of polypharmacy or
concomitant treatment with other QT-prolonging drugs such as fluoroquinolones.
Macrolide-induced ototoxicity typically affects the lower (speech) frequencies and is usually
characterised by a bilateral sensorineural hearing loss, often reversible [157]. This rare
side-effect is dose dependent and facilitated by risk factors such as renal impairment, as
was demonstrated in one prospective case–control study in pneumonia patients treated with
intravenous erythromycin [166]. Azithromycin-induced hearing loss has been reported in
case of long-term high dosage (e.g. 500 mg daily) and mostly within a context of treatment
of NTM infections [167, 168]. However, its incidence during low-dose long-term treatment
still needs to be established [157], although one study in COPD patients observed more
hearing decrements in participants receiving azithromycin than in those receiving placebo
[19]. While routine audiometric screening is not considered mandatory, some authors
suggest ordering audiometry before initiation of therapy in risk groups [169].
Long-term macrolide treatment will undoubtedly have an influence on the respiratory
microbiome. A subanalysis of the BLESS (Bronchiectasis and low-dose erythromycin study)
trial showed that in patients with non-CF bronchiectasis who were not colonised with
P. aeruginosa, erythromycin caused a shift in the microbiome from a dominant presence of
H. influenzae to an increase in concentration of P. aeruginosa [17]. Further research on this
important area needs to be performed to investigate whether this change in the microbiome
will also influence the clinical outcome.
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Macrolide resistance
Prescription of macrolides has been associated with emerging resistance, mainly in
Streptococcus spp. and Staphylococcus spp. [170–174]. Unfortunately, few RCTs assessing
long-term macrolide maintenance therapy have monitored for resistance induction. In CF
patients, increased macrolide resistance has been observed during long-term macrolide
treatment in Staphylococcus aureus and H. influenzae, particularly after multiple years of
therapy [175–178]. As the clinical benefit of azithromycin in CF seems to be limited to the
first 6–12 months of treatment [101], implementing shorter treatment courses and periods of
treatment interruption might help to tackle resistance development. Similarly, a meta-analysis
of RCTs in non-CF bronchiectasis documented an increased risk of macrolide resistance in
H. influenzae, S. aureus and S. pneumoniae [179], while COPD trials did not find increased
appearance of macrolide-resistant organisms after 3–12 months of therapy [20, 180].
Although macrolide resistance is increasing among pneumococcal isolates, literature on its
clinical significance in severe infections such as pneumococcal pneumonia is inconsistent,
but does not show a significant increase in mortality [181–184]. A recent retrospective
study in a tertiary care hospital found no evidence suggesting that adult patients
hospitalised with macrolide-resistant pneumococcal pneumonia experienced a more severe
clinical presentation or worse clinical outcome than those with positive cultures for
macrolide-susceptible S. pneumoniae [185]. From a population point of view, however, it
remains important to restrict chronic macrolide use to those patients who will benefit the
most in view of the increasing resistance data.
The occurrence of macrolide resistance is facilitated by macrolide monotherapy in the
treatment of MAC lung disease and macrolide susceptibility is key to treatment success
[186]. As azithromycin is able to block autophagosome clearance by preventing lysosomal
acidification in primary human macrophages, leading to impairment of autophagy and,
consequently, inhibition of intracellular killing of mycobacteria, some authors fear the
induction of (macrolide-resistant) mycobacterial infection during long-term azithromycin
use [187]. However, a nested case–control study in one large CF centre recently showed a
reduced risk of NTM in CF adults receiving long-term azithromycin, making a plea for its
use as primary prophylaxis against NTM [188]. Nevertheless, before initiating macrolide
treatment, ideally three sputum samples should be delivered to exclude pre-existing NTM
disease in predisposing conditions such as CF and bronchiectasis. Furthermore, current
guidelines advise not to continue azithromycin treatment if a positive NTM culture is
obtained in CF patients, unless as part of a multidrug treatment regimen in the context of
NTM disease [189]. Recommendations for long-term macrolide treatment monitoring are
summarised in table 3.
Conclusions
The pleiotropic effects of macrolides such as erythromycin, clarithromycin and
azithromycin encompass anti-inflammatory and immunomodulatory capacities, in addition
to their antimicrobial effects. The beneficial effects of macrolides have almost unequivocally
been accepted in chronic inflammatory airway diseases such as diffuse panbronchiolitis, CF,
non-CF bronchiectasis, COPD and severe noneosinophilic asthma (table 4). However, when
macrolides are widely used in the community, population antimicrobial resistance will
possibly increase. Therefore, indications to start macrolides should be very carefully
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considered, particularly when used in common diseases such as COPD and asthma, and
well monitored (table 3). Azithromycin 500 mg three times weekly (MWF) is the regimen
of first choice. In general, long-term macrolides should be considered in the described
diseases when patients present with at least two exacerbations per year despite optimal
treatment with the ordinary medications as recommended in the relevant guidelines.
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